Information on whether talquetamab-tgvs has been marketed in China

Talquetamab, trade name: Talquetamab, is not currently available in China, but is expected to be officially launched in February 2025. As an innovative therapeutic drug for relapsed or refractory multiple myeloma, the launch of Taquitumab will undoubtedly bring a new treatment option to Chinese patients.

Currently, Taquitumab has been approved in many countries around the world and has entered the practical application stage. In the United States, taquinutumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma who have received at least four different treatment regimens. The successful launch of this drug provides new hope for the global treatment of multiple myeloma, especially for drug-resistant patients, and its efficacy has been widely recognized in clinical practice.

In China, Tacutumumab is also in the process of regulatory approval and is expected to officially enter the market on February 8, 2025 under the trade name "Tolic". Its approval will fill the domestic treatment gap for relapsed or refractory multiple myeloma, especially for those patients who have become resistant to conventional treatments. Taquitumab provides a new treatment approach. The launch of this drug is expected to bring revolutionary changes to multiple myeloma patients in China, while also promoting the further development of domestic anti-cancer drug research and development and clinical application.

With the launch of the drug, Tacistumumab will not only provide new treatment options, but will also promote the improvement of therapeutic effects and quality of life for Chinese multiple myeloma patients. In the future, with the further improvement of the domestic medical system, Tacistumumab is expected to become one of the standard therapies for the treatment of relapsed multiple myeloma in China.

Reference materials:https://www.talveyhcp.com/